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Edited by Judit Ova´diAbstract The eﬀect of a serine protease (ASP) secreted from
Aeromonas sobria on plasma coagulation was investigated.
Proteolytically active ASP promoted human plasma coagulation
in a dose-dependent manner. Consistent with the preference for a
factor Xa-speciﬁc oligo-peptide substrate, ASP produced enzy-
matic activity from human prothrombin but not from factors
IX and X. ASP cleaved prothrombin to produce enzymatically
active 37 kDa-fragment displaying the same molecular mass as
a-thrombin. ASP is the ﬁrst bacterial serine protease that
produces a-thrombin, through which ASP may contribute to
the induction of thrombotic tendency in disseminated intravascu-
lar coagulation complicated with sepsis caused by A. sobria
infections.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Aeromonas species are facultative anaerobic, Gram-negative
rods [1]. Aeromonas infection commonly presents through the
digestive tract, with associated gastroenteritis and often devel-
ops to sepsis [1,2]. Shock and disseminated intravascular coag-
ulation (DIC) are common and deadly consequence in the
sepsis patients, with a high mortality rate. As a putative viru-
lence factor we have puriﬁed a 65 kDa-serine protease (ASP)
from the culture supernatant of Aeromonas sobria [3], which
is more virulent than other Aeromonas species. ASP induces
vascular leakage and blood pressure lowering through activa-
tion of the kallikrein/kinin system [3]; suggesting an involve-
ment of ASP in the septic shock. Whether ASP is associated
with the induction of DIC has yet to be elucidated.
Thrombotic tendency is a prominent clinical feature of DIC
that occurs in as many as 40% of sepsis patients and often
leads to multiple organ failure [4]. The coagulation system is*Corresponding author. Fax: +81 96 373 5308.
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doi:10.1016/j.febslet.2007.11.076initiated by complex formation of tissue factor and factor
VII/VIIa [5], and mediated by a cascade reaction of the prote-
olytic activation of factors IX, X and prothrombin, leading to
the ultimate product a-thrombin, which converts ﬁbrinogen to
a ﬁbrin clot and causes platelet aggregation. It is generally ac-
cepted that the DIC associated with sepsis is triggered by the
expression of tissue factor on monocytes and endothelial cells
activated by endotoxins, and/or cytokines released from vari-
ous cells, including leukocytes, stimulated by the infection
[6]. However, bacterial proteases, released into the circulation
during sepsis, possibly activate either of the zymogens of the
coagulation system, and ultimately yield a-thrombin. To study
the potential virulence activity of ASP through interaction
with plasma proteins, we investigated the eﬀect of ASP on acti-
vating the coagulation system.2. Materials and methods
2.1. Materials
Human prothrombin, factors IX and X, were purchased from
Enzyme Research Laboratories. Methylsulphonyl-D-cyclohexylglycyl-
glycyl-L-arginine-4-methylcoumaryl-7-amide (MS-D-CHG-Gly-Arg-
MCA) was purchased from Pentapharm Ltd. (Basel, Switzerland).
Other MCA substrates were obtained from the Peptide Institute (Min-
oh, Japan). Human a-thrombin was purchased from Calbiochem (San
Diego, CA, USA). Thromborel S and STA APTT reagent were pur-
chased from Dade Behring (Eschborn, Germany) and from Diagnosti-
ca Stago (Asnie`res, France), respectively. Horseradish peroxidase
conjugated-streptavidin and biotinylated Phe-Pro-Arg-chloromethyl-
ketone were purchased from Wako Pure Chemical Industries (Osaka,
Japan) and Bachem (King of Prussia, PA, USA), respectively. Other
chemicals were purchased from Wako Pure Chemical Industries (Osa-
ka, Japan). Normal human plasma was prepared by centrifugation of a
mixture of 9 volumes of freshly drawn blood from healthy volunteers
and 1 volume of 3.8% (w/v) sodium citrate.2.2. Puriﬁcation of ASP
ASP was puriﬁed from the culture supernatant of a clinically iso-
lated A. sobria strain, according to the method described previously
[3]. Enzyme preparations demonstrated to be homogenous, revealing
a single 65 kDa band on an SDS–polyacrylamide gel under both re-
duced and non-reduced conditions [3].
2.3. Clotting assay
Plasma coagulation time was measured with KC4D (Trinity Biotech,
Bray, Ireland) according to the method detailed previously [7].blished by Elsevier B.V. All rights reserved.
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Ten microliter of an MCA substrate (10 mM) was added to 600 ll of
ASP solution (10 nM in 50 mM Tris–HCl, pH 7.4, containing 0.1 M
NaCl) and incubated at 37 C, measuring 7-amino-4-methyl coumarin
(AMC) (ﬂuorescence at 440 nm with excitation at 380 nm) with ﬂuo-
rescence spectrophotometer (Model 650-40, Hitachi) monitored with
a recorder. For the activated coagulation factor assay, 10 mM Boc-As-
p(OBzl)-Pro-Arg-MCA (for thrombin) [8], 10 mM Z-Pyr-Gly-Arg-
MCA (for factor Xa) [8] or 5 mM MS-D-CHG-Gly-Arg-MCA (for
factor IXa) [9] were used. In the case of the activated factor IX assay,
the buﬀer was supplemented with ethylene glycol (30% ﬁnal concentra-
tion) to enhance the catalytic activity of factor IXa against the sub-
strate [9,10].Table 1
Cleavage of various oligo-peptide substrates by ASP
Substrate AMC release (nM/min)
Boc-Ile-Glu-Gly-Arg-MCA 82
Boc-Leu-Ser-Thr-Arg-MCA 64
Pyr-Arg-Thr-Lys-Arg-MCA 45
Boc-Glu-Lys-Lys-MCA 45
Boc-Leu-Lys-Arg-MCA 7.0
Boc-Phe-Ser-Arg-MCA 2.2
Boc-Asp(OBzl)-Pro-Arg-MCA 2.0
Boc-Glu(OBzl)-Ala-Arg-MCA 1.8
Boc-Leu-Thr-Arg-MCA 1.5
Boc-Val-Leu-Lys-MCA 1.3
Boc-Gly-Arg-Arg-MCA 1.0
Z-Pyr-Gly-Arg-MCA 0
Pro-Phe-Arg-MCA 0
Z-Phe-Arg-MCA 0
Boc-Gln-Gly-Arg-MCA 0
Boc-Leu-Gly-Arg-MCA 0
Pyr-Gly-Arg-MCA 0
Arg-MCA 0
Suc-Ala-Ala-Pro-Phe-MCA 1.8
Suc(OMe)-Ala-Ala-Pro-Val-MCA 1.2
Gly-Pro-MCA 0.4
Ac-Asp-Glu-Val-Asp-MCA 0.4
Boc, t-buthyloxycarbonyl; Pyr, L-pyroglutamyl; Asp(OBzl), [-(2S)-
2-amino-3-(benzylocarbonyl)propionyl]; Glu(OBzl), [-(2S)-2-amino-
3-(benzylocarbonyl)butanoyl]; Z, benzyloxycarbonyl; Suc, succinyl;
Suc(OMe), N-methoxysuccinyl; Ac, acetyl.
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Fig. 1. Promotion of plasma coagulation by ASP. (A) Activated partial throm
microliter of plasma and 5 ll of protease were incubated in a plastic cell at 37
was incubated for 3 min, and after the addition of 50 ll of 25 mM CaCl2, t
plasma incubated with ASP. Forty-ﬁve microliter of plasma and 5 ll of ASP
Thromborel S was added and the clotting time was measured. ASP concen
inactivated ASP. Dashed lines are the borders of controls which were assa
instead of ASP. *P < 0.01 versus controls.2.5. Blotting of enzymatically active thrombin
Enzymatically active thrombin was detected using biotinylated Phe-
Pro-Arg-chloromethylketone [11].
2.6. Statistics
Statistical analysis was performed using an unpaired Students t-test.
Values were expressed as means ± S.D. (n = 4).3. Results
3.1. Cleavage of oligo-peptide substrates by ASP
ASP cleaved some substrates with Arg at the P1 site, espe-
cially those that contained a hydrophobic amino acid at the
P4 site, whilst little or no cleavage was observed for other sub-
strates with Arg at the P1 site (Table 1). In accordance with its
high structural similarity to furin [12], ASP also cleaved sub-
strates with paired basic amino acid residues at the carboxy-
terminus, but had negligible activity for substrates with an
amino acid residue other than Arg at the P1 site.
3.2. Eﬀect of ASP on human plasma coagulation
Human plasma was incubated with ASP and examined
APTT for the intrinsic coagulation pathway. ASP shortened
APTT in a dose-dependent manner at concentrations as low
as 30 nM (Fig. 1A). Since ASP treated with DFP, a serine pro-
tease-speciﬁc inhibitor, did not aﬀect APTT, the proteolytic
activity of the enzyme must be linked to its coagulation pro-
moting eﬀects. ASP exerted a similar eﬀect on the extrinsic
coagulation pathway, as seen by PT shortening in a dose-
and protease activity-dependent manner (Fig. 1B). ASP itself
did not convert human ﬁbrinogen to a ﬁbrin clot (data not
shown). These results suggest that enzymatically active ASP
can promote plasma coagulation in both of the coagulation
pathways.
3.3. Eﬀect of ASP on coagulation factor zymogens
The eﬀect of ASP on both coagulation pathways (Fig. 1A
and B) indicates that ASP activates any of factors IX, X, or
prothrombin, common factors to both pathways. ASP gener-10
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boplastin time (APTT) of human plasma treated with ASP. Forty-ﬁve
C for 1 min, followed by the addition of 50 ll STA APTT. The mixture
he clotting time was measured. (B) Prothrombin time (PT) of human
were incubated in a plastic cell at 37 C for 3 min. Fifty microliter of
trations in plasma are shown. (s) non-treated ASP; () DFP (1 mM)-
yed using 10 mM Tris–HCl, pH 7.4, containing 150 mM NaCl (TBS)
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Fig. 2. Activation of coagulation factors by ASP. Ninety microliter of a human coagulation factor (1.1 lM dissolved in 50 mM Tris–HCl, pH 7.4,
containing 0.1 M NaCl and 5 mM CaCl2) was incubated with 10 ll of ASP at 37 C, then added to 500 ll of 0.1 M Tris–HCl, pH 7.6, containing
150 mM NaCl. To this mixture, 10 ll of an MCA-substrate (10 mM) speciﬁc for the activated form of the coagulation factor was added and AMC
released was measured. (A) A coagulation factor was incubated with ASP at various concentrations at 37 C for 5 min. (B) ASP (50 nM ﬁnal
concentration) was incubated with or without 1 lM of prothrombin at 37 C for various periods. The ASP concentrations in the reaction mixture are
shown. (s), prothrombin; (n), factor X; (h), factor IX. Closed circles indicate prothrombin incubated with DFP-treated ASP.
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and incubation time-dependent manner, but produced no
enzymatic activity from factors IX and X (Fig. 2). DFP-treated
ASP did not release thrombin activity (Fig. 2), and ASP
showed negligible cleaving activity for the thrombin substrate
(Table 1). It is clear that ASP speciﬁcally activates prothrom-
bin.
3.4. Cleavage of prothrombin by ASP
Multiple autocatalytic forms of a-thrombin have been re-
ported as molecules smaller than the native a-thrombin; and
the major forms, b- and c-thrombin, are also enzymatically ac-
tive against small synthetic substrates [13]. Consistent with the
rapid thrombin activity generation (Fig. 2), ASP cleaved pro-
thrombin within 1 min, and released major fragments of 55,
37, 29 and 24 kDa in 15 min. The 37 kDa-fragment migrated
to the a-thrombin region (Fig. 3A). Biotinylated Phe-Pro-
Arg-chloromethylketone labeling of the active thrombin forms
generated during prothrombin incubation with ASP provided
evidence that the 37 kDa-fragment was an enzymatically active29
24
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Fig. 3. (A) Cleavage of prothrombin by ASP. Ninety microliters of prothrom
5 mM CaCl2) and 10 ll of ASP (1 lM) were incubated for various time period
applied to an SDS–polyacrylamide gel (19 lg protein/lane). (a) Prothrombin
respectively; (f) a-thrombin (0.5 lg). Coomassie Brilliant Blue R-250 was use
generated during prothrombin incubation with ASP. Prothrombin was incub
aliquots were incubated with 11 lM biotinylated Phe-Pro-Arg-chloromethy
polyacrylamide gel (10%), followed by electro-transfer onto a polyvinylid
conjugated streptavidin, and bands were developed by enhanced chemilum
incubated with ASP for 1, 15, 30, 60, 90 min, respectively; (g) a-thrombin (0serine protease, as is a-thrombin (Fig. 3B). The 55 kDa- and
72 kDa-molecules also incorporated this inhibitor (Fig. 3B).
The 72 kDa-molecule, which is the same molecular mass as
prothrombin, appeared in 1 minute; followed by production
of the 55 kDa- and 37 kDa-fragments, which indicates that
ASP generates a-thrombin by cleaving prothrombin at three
sites.4. Discussion
The ASP-elicited shortening of both APTT and PT (Fig. 1A
and B) indicates that this protease, when released into the
blood stream in A. sobria sepsis, promotes plasma coagulation,
which can be associated with the development of DIC. We
have shown that the 37 kDa-fragment generated by ASP-trea-
ted prothrombin had a molecular weight akin to a-thrombin
(Fig. 3), cleaved an a-thrombin-speciﬁc synthetic substrate
(Fig. 2A and B), and incorporated a serine protease inhibitor
(Fig. 3). Moreover, high-throughput N-terminal sequencinga        b       c       d       e       f         g
bin (20 lM in 50 mM Tris–HCl, pH 7.4, containing 0.1 M NaCl and
s. Fifteen microliters of the mixture was treated with DFP (1 mM) and
alone; (b–e) prothrombin incubated with ASP for 1, 15, 30, 90 min,
d for protein staining. (B) Blotting of active-site biotinylated thrombin
ated with ASP as described in Fig. 2. At various time periods, 15 ll of
lketone for 10 min at room temperature and analyzed on an SDS–
ene ﬂuoride membrane. The membrane was incubated with HRP-
inescence. (a) Prothrombin alone (19 lg); (b–f) prothrombin (19 lg)
.3 lg).
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tech, Kyoto, Japan) and a MALDI-TOF/TOF mass-spectro-
meter (Applied Biosystems, Framingham, MA) revealed the
presence of N-terminal fragments (TATSEYQTFFNPR and
IVEGSDAEIGMSPWQVMLFR) identical to the sequences
of a-thrombin light and heavy chains [14], respectively (data
not shown). These data clearly demonstrate that a-thrombin
production is the mechanism of coagulation promotion by
ASP. In comparison with indirect generation, as mediated by
factor IXa and/or Xa the generation of a-thrombin lessens
the opportunities for regulation by plasma protease inhibitors
and a-thrombin can convert ﬁbrinogen to ﬁbrin in the absence
of phospholipids, important cofactors in blood coagulation.
Furthermore, platelet aggregation was induced by ASP-treated
prothrombin (data not shown), which, together with the insti-
gation of coagulation, would lead to the formation of thrombi,
the most characteristic symptom of DIC [4]. Thus, ASP med-
iated a-thrombin production likely contributes to the induc-
tion of DIC.
Meizothrombin is produced from prothrombin via the cleav-
age at Arg320 and Ile321, yielding enzymatic activity without
any reduction in molecular weight [14]. Our observation that
the 72 kDa-molecule had the same molecular weight as pro-
thrombin, and was labeled with biotinylated Phe-Pro-Arg-
chloromethylketone (Fig. 3B), suggests that this molecule is
probably meizothrombin. The shift from 72 kDa to 55 kDa
appears to occur by the action of ASP via cleavage at the site
between fragment 1 and fragment 2, where there is no disulﬁde
bond connection of the two fragments, thus releasing a mole-
cule similar to fragment 1. At this step, the involvement of mei-
zothrombin autolysis [15] cannot be excluded. Next, ASP
probably cuts oﬀ fragment 2 from the 55 kDa-fragment by
cleaving between Arg271 and Thr272, producing a-thrombin
(37 kDa). The fact that ASP could cleave peptide bonds after
arginine residues (Table 1), as seen in human prekallikrein acti-
vation (-Arg371  ﬂ-Ile372-) [3], agrees with the cleavage sites
requisite for a-thrombin production from human prothrombin
(-Arg271  ﬂ-Thr272- and -Arg320  ﬂ-Ile321-) [14]. It does,
however, conﬂict with the result that ASP did not activate fac-
tors IX and X (Fig. 2A and B), as these factors are also acti-
vated by cleavage of peptide bonds after arginine residues
[16,17]. ASP is a subtilisin-like protease [12,18], and subtilisin
prefers hydrophobic side chains at the S4 subsite [19]. In fact,
ASP cleaved most eﬃciently a factor Xa-speciﬁc substrate Boc-
Ile-Glu-Gly-Arg-MCA [8], which has a hydrophobic amino
acid Ile at the P4 site (Table 1). As shown in Fig. 4, the P4 res-
idues are Ile at both cleavage sites necessary for a-thrombin
production; and Lys and Asp, and Asn for activation of factor
IX or X, respectively [14,16,17]. The diﬀerence in P4 residues atFig. 4. The amino acid sequences including cleavage sites requisite for
activation of coagulation factors. Bold letters and underlined letters
indicate P1 site and P4 site residues, respectively. *,#,##Data obtained
from [14], [16], and [17], respectively.the cleavage sites requisite for activation of these zymogens is
the reason why ASP activates prothrombin but not factors IX
and X.
Cysteine proteases (gingipains-R) produced by Porphyro-
monas gingivalis [11], and metalloproteases from Staphylococ-
cus aureus [20] or Vibrio vulniﬁcus [21], have been shown to
activate human prothrombin. Metalloproteases from Serratia
marcescens and Pseudomonas aeruginosa were reported to be
capable of releasing thrombin activity from bovine prothrom-
bin [22]. No serine protease of bacterial origin has been re-
ported as a prothrombin activator, thus ASP is currently the
only bacterial serine protease shown to possess this ability.
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